Brief: Pulmatrix - In Discussions With Cipla On Termination Of Pulmazole Phase 2 Clinical Study & Initiation Of New Phase 2B/ 3 Clinical Study During In Mid-2021
09/07/2020 14:34
July 9 (Reuters) - Pulmatrix Inc PULM.O :
* PULMATRIX - IN DISCUSSIONS WITH CIPLA ON TERMINATION OF
PULMAZOLE PHASE 2 CLINICAL STUDY & INITIATION OF NEW PHASE 2B/ 3
CLINICAL STUDY DURING IN MID-2021
Source text for Eikon: [ID: https://bit.ly/3205FxJ]
Further company coverage: PULM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pulmatrix
See all newsBrief: Pulmatrix Announces Second Quarter 2026 Financial Results And Progress On Merger
Pulmatrix Q2 loss narrows on clinical development hold
Pulmatrix Q1 net loss narrows, clinical development on hold
Brief: Pulmatrix Announces Closing Of Preferred Stock Transaction As Part Of Planned Merger
NASDAQ RESUMED AT 09:00 AM